Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | DBH | P09172 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463290 | 1.00 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL30413844 | 0.84 | MAPT (0.53) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL3792476 | 0.84 | MAPT (0.53) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL580639 | 0.83 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL29725217 | 0.83 | CA2 (0.47) | MAPTSMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2500053 | 0.83 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL2296988 | 0.83 | CA2 (0.47) | MAPTSMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL29559892 | 0.83 | CA2 (0.68) | MAPTALDH1A1KDM4ECA2POLB | |
| SCHEMBL1080853 | 0.83 | CA2 (0.68) | MAPTALDH1A1KDM4ECA2POLB | |
| SCHEMBL2495130 | 0.82 | HTR7 (0.58) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | SHANGHAI MEDICILON INC. (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20250222145-A1 | TRACER COMPOSITION FOR RADIOACTIVE PET DIAGNOSIS, INTERMEDIATE THEREOF, AND PRODUCTION METHOD THEREOF | OSAKA UNIVERSITY (JP) | 2025-07-10 | — | — | US | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| WO-2023063154-A1 | TRACER COMPOSITION FOR RADIOACTIVE PET DIAGNOSIS, INTERMEDIATE THEREOF, AND PRODUCTION METHOD THEREOF | 国立大学法人大阪大学 | 2023-04-20 | — | — | WO | disclosed |
| US-20220259214-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | SHANGHAI MEDICILON INC. (CN) | 2022-08-18 | — | — | US | disclosed |
| US-20030153587-A1 | Polycyclic guanine phosphodiesterase V inhibitors | SCHERING CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| EP-1319003-A1 | XANTHINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003042216-A1 | POLYCYCLIC GUANINE DERIVATIVE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003042216-A1 | POLYCYCLIC GUANINE DERIVATIVE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003020724-A1 | POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020724-A1 | POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169174-A1 | Xanthine phosphodiesterase V inhibitors | MERCK SHARP & DOHME CORP. | 2002-11-14 | — | — | US | disclosed |
| CN-1374952-A | Benzimidazolone derivatives and their use as phosphodiesterase inhibibors | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-16 | — | — | CN | disclosed |
| WO-2002024698-A1 | XANTHINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153587-A1 | Polycyclic guanine phosphodiesterase V inhibitors | PDE5A, PDE3A, PDE2A | MAPT 4798/4885SMN1; SMN2 3001/4885L3MBTL1 4475/4885 |
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | MAPT 1141/4885SMN1; SMN2 998/4885L3MBTL1 4767/4885 |
| US-20020169174-A1 | Xanthine phosphodiesterase V inhibitors | PDE5A, PDE3B, PDE3A | MAPT 3833/4885SMN1; SMN2 3076/4885L3MBTL1 4557/4885 |
| US-20220259214-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | PGC, ABCB11, ATP1A2 | MAPT 4205/4885SMN1; SMN2 4734/4885L3MBTL1 4793/4885 |
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | GIPR, PGC, GRPR | MAPT 3777/4885SMN1; SMN2 4351/4885L3MBTL1 4318/4885 |
| US-20250222145-A1 | TRACER COMPOSITION FOR RADIOACTIVE PET DIAGNOSIS, INTERMEDIATE THEREOF, AND PRODUCTION METHOD THEREOF | BCAT2, SLC7A1, BCAT1 | MAPT 593/4885SMN1; SMN2 3602/4885L3MBTL1 147/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | MAPT 1236/4885SMN1; SMN2 1164/4885L3MBTL1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.